Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Kwang‐Yu Chang(National Health Research Institutes), Li-Tzong Chen(Kaohsiung Medical University), Katherine Wu(New York University), Peter W. Szlosarek(St Bartholomew's Hospital), Bor-Wen Wu(Polaris (United States)), Nai‐Jung Chiang(National Yang Ming Chiao Tung University), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Shalini S. Yadav(The University of Texas MD Anderson Cancer Center), Jorge Blando(AstraZeneca (Netherlands)), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Chien‐Feng Li(National Sun Yat-sen University), Xiaoxing Feng(Polaris (United States)), Amanda Johnston(Polaris (United States)), Chia-Jui Yen(National Cheng Kung University), Yu-Min Yeh(National Cheng Kung University Hospital), Shang-Yin Wu(National Cheng Kung University Hospital), John S. Bomalaski(Polaris (United States)), Shang-Hung Chen(National Health Research Institutes), Sumit K. Subudhi(The University of Texas MD Anderson Cancer Center)
Cited by 44
Related Papers
A Python library for probabilistic analysis of single-cell omics data
|Nature Biotechnology|2022|815
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
|Cancer Cell|2020|398